China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
MENLO PARK, Calif., Feb. 04, 2016 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it will present at the Leerink Partners 5th Annual Global Healthcare Conference. Tom Wiggans, chairman and chief executive officer of Dermira, is scheduled to present at 11:35 a.m. ET on Thursday, February 11, 2016, in New York. A live audio webcast and replay of the presentation will be available in the Investors section of Dermira’s corporate website at www.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases. Dermira’s portfolio of five product candidates targets significant market opportunities and includes three late-stage product candidates: CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, in Phase 3 development for the treatment of axillary hyperhidrosis; and DRM01, in Phase 2b development for the treatment of acne. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 [email protected] Investor Contact Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 [email protected]
